Malignant Ascites Clinical Trial Pipeline Accelerates: 5+ Companies Driving Innovation in Next-Generation Therapies | DelveInsight

DelveInsight's report, "Malignant Ascites Pipeline Insight 2026," delivers in-depth analysis of more than 5 companies and 5+ investigational therapies shaping the malignant ascites pipeline landscape. The report provides detailed profiles of pipeline candidates across both clinical and preclinical stages. It further evaluates the therapeutic landscape based on product type, development stage, route of administration (ROA), and molecule classification, while also identifying discontinued or inactive programs within this domain.

Explore the latest innovations in malignant ascites research and development. Gain deeper insights into our evolving pipeline landscape @ Malignant Ascites Pipeline Outlook-
https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Malignant Ascites Pipeline Report
• On February 09, 2026, Dong sheng Zhang initiated a Phase II expansion study to assess the safety and efficacy of liposomal irinotecan, either as a standalone therapy or in combination with recombinant modified human tumor necrosis factor or bevacizumab, for treating malignant peritoneal effusion in patients who have not responded to standard treatments.
• DelveInsight's analysis highlights a dynamic pipeline, with 5+ active companies advancing over 5 investigational therapies targeting malignant ascites.
• Key players in this space include Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others.
• Prominent therapies under development include M701, Paracentesis, Alfapump, and additional novel candidates.

Stay updated on the latest therapeutic advancements in malignant ascites. Access detailed insights and join the evolution of treatment approaches @ Malignant Ascites Clinical Trials Assessment-
https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Malignant Ascites Overview
Ascites refers to the abnormal accumulation of fluid within the abdominal cavity. When this condition arises due to cancer, it is termed malignant ascites. It is commonly associated with cancers such as colorectal, breast, lung, pancreatic, liver cancers, and lymphoma. Around 50% of patients with malignant ascites experience peritoneal carcinomatosis, while approximately 13% develop the condition due to extensive liver metastases leading to portal hypertension.
The condition can occur through multiple mechanisms, including obstruction of lymphatic drainage due to tumor growth, excessive fluid secretion by aggressive malignancies, or the onset of functional cirrhosis caused by widespread liver metastases. Malignant ascites is linked with a poor clinical outlook, with median survival typically ranging between 1 to 4 months.

Emerging Drugs for Malignant Ascites
SCB-313: Clover Biopharmaceuticals
Leveraging its proprietary Trimer-TagTM platform, Clover Biopharmaceuticals has developed SCB-313, a structurally advanced trimeric fusion protein designed to mimic native biological activity. Unlike conventional dimeric antibody-based therapies, this innovative candidate offers differentiated functional properties. SCB-313 is being investigated for the treatment of malignant ascites, malignant pleural effusion (MPE), and peritoneal carcinomatosis, addressing significant unmet needs in intracavitary cancers. The therapy is currently undergoing Phase I clinical evaluation.

Explore emerging drug opportunities and pipeline advancements in malignant ascites @ Malignant Ascites Unmet Needs- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Malignant Ascites Space
Major companies involved in developing therapies for malignant ascites include Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others.

Therapeutic Assessment by Route of Administration (ROA)
Pipeline therapies are categorized based on their administration routes, including:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Therapeutic Assessment by Molecule Type
Malignant ascites pipeline products are further classified by molecule type, such as:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Discover ongoing advancements shaping the malignant ascites treatment landscape and future outlook @ Malignant Ascites Market Drivers and Barriers, and Future Perspectives-
https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Malignant Ascites Pipeline Report
• Geographical Coverage: Global
• Key Companies: Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others
• Key Therapies: M701, Paracentesis, Alfapump, among others
• Assessment by Product Type: Monotherapy, Combination, and Mono/Combination
• Assessment by Development Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

For comprehensive insights into pipeline developments and future opportunities, access the full report @ Malignant Ascites Emerging Drugs and Companies-
https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Malignant Ascites Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. DelveInsight Analytical Perspective
7. Mid-Stage Products (Phase II)
8. Drug Profiles
9. Early-Stage Products (Phase I)
10. SCB-313: Clover Biopharmaceuticals
11. Inactive Products
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.